<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>3</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art16">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>71149</ArticleID>
            <ArticleDOI>10.1208/aapsj070116</ArticleDOI>
            <ArticleSequenceNumber>16</ArticleSequenceNumber>
            <ArticleTitle Language="En">Oral bioavailability in pigs of a miconazole/Hydroxypropyl-γ-cyclodextrin/ L-tataric acid inclusion complex produced by supercritical carbon dioxide processing</ArticleTitle>
            <ArticleFirstPage>E149</ArticleFirstPage>
            <ArticleLastPage>E155</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>28</Day>
              </RegistrationDate>
              <Received>
                <Year>2004</Year>
                <Month>10</Month>
                <Day>15</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>1</Month>
                <Day>20</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>1</IssueIDStart>
              <IssueIDEnd>1</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Valéry</GivenName>
                  <FamilyName>Barillaro</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>+32 4 3664301</Phone>
                  <Fax>+32 4 366 43 02</Fax>
                  <Email>v.barillaro@ulg.ac.be</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Brigitte</GivenName>
                  <FamilyName>Evrard</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Luc</GivenName>
                  <FamilyName>Delattre</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Géraldine</GivenName>
                  <FamilyName>Piel</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Laboratory of Pharmaceutical Technology, Department of Pharmacy</OrgDivision>
                <OrgName>University of Liège</OrgName>
                <OrgAddress>
                  <Street>CHU-Tour 4, Bât B36 Avenue de l'Hopital, 1</Street>
                  <Postcode>B-4000</Postcode>
                  <City>Liège 1</City>
                  <Country>Belgium</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The objective of this study was to determine the pharmacokinetic parameters of miconazole after oral administration of a miconazole/hydroxypropyl-γ-cyclodextrin(HPγCD)/ L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing. The pharmacokinetics of the miconazole ternary complex (CPLX), of the corresponding physical mixture (PHYS), and of miconazole alone (MICO) were compared after oral administration. Six mixed-breed pigs received each formulation as a single dose (10 mg miconazole/kg) in a crossover design. Miconazole plasma concentrations were determined by a high-performance liquid chromatography method. Preliminary in vitro dissolution data showed that CPLX exhibits a faster and higher dissolution rate than either PHYS or MICO. Following CPLX oral administration, mean area under the plasma concentration curve (AUC<Subscript>0−∞</Subscript>) for miconazole was 95.0±55.8 μg/min/mL, with the peak plasma concentration (C<Subscript>max</Subscript> 0.59±0.39 μg/mL) at 19.30 minutes. The AUC<Subscript>0−∞</Subscript> and C<Subscript>max</Subscript> values were significantly higher than those after oral administration of PHYS (AUC<Subscript>0−∞</Subscript> 38.5±12.7 μg/min/mL and C<Subscript>max</Subscript> 0.24±0.08 μg/mL;<Emphasis Type="Italic">P</Emphasis>&lt;.1) and of MICO (AUC<Subscript>0−∞</Subscript> 24.1±14.0 μg/min/mL and C<Subscript>max</Subscript> 0.1±0.05 μg/mL;<Emphasis Type="Italic">P</Emphasis>&lt;.1). There were also significant differences between PHYS and MICO (<Emphasis Type="Italic">P</Emphasis>&lt;.1). The results of the study indicate that CPLX shows improved dissolution properties and a higher relative oral bioavailability compared with PHYS and MICO.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>oral bioavailability</Keyword>
              <Keyword>supercritical carbon dioxide</Keyword>
              <Keyword>multicomponent inclusion complex</Keyword>
              <Keyword>cyclodextrin</Keyword>
              <Keyword>miconazole</Keyword>
              <Keyword>dissolution test</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: August 18, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_71149.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Gelderblom</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Verweij</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Nooter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Sparreboom</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation</ArticleTitle>
                  <JournalTitle>Eur J Cancer.</JournalTitle>
                  <VolumeID>37</VolumeID>
                  <FirstPage>1590</FirstPage>
                  <LastPage>1598</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11527683</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0959-8049(01)00171-X</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXmt1Oqtb0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.<Emphasis Type="Italic">Eur J Cancer.</Emphasis> 2001;37:1590–1598.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Loftsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Brewster</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization</ArticleTitle>
                  <JournalTitle>J Pharm Sci.</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>1017</FirstPage>
                  <LastPage>1025</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8897265</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/js950534b</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XlsFSrsr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 1996;85:1017–1025.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Jacobsen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Bjerregaard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Pedersen</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR146 cells and release from a delivery system</ArticleTitle>
                  <JournalTitle>Eur J Pharm Biopharm.</JournalTitle>
                  <VolumeID>48</VolumeID>
                  <FirstPage>217</FirstPage>
                  <LastPage>224</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10612032</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0939-6411(99)00043-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXhtl2itw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jacobsen J, Bjerregaard S, Pedersen M. Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR146 cells and release from a delivery system.<Emphasis Type="Italic">Eur J Pharm Biopharm.</Emphasis> 1999;48:217–224.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Mura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Liguori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Bramanti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GP</Initials>
                    <FamilyName>Bettinetti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Campisi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Faggi</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Improvement of dissolution properties and microbiological activity of miconazole and econazole by cyclodextrin complexation</ArticleTitle>
                  <JournalTitle>Eur J Pharm Biopharm.</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>119</FirstPage>
                  <LastPage>123</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXitF2lsrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mura P, Liguori A, Bramanti G, Bettinetti GP, Campisi E, Faggi E. Improvement of dissolution properties and microbiological activity of miconazole and econazole by cyclodextrin complexation.<Emphasis Type="Italic">Eur J Pharm Biopharm.</Emphasis> 1992;38:119–123.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Pedersen</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Isolation and antimycotic effect of a genuine miconazole β-cyclodextrin complex</ArticleTitle>
                  <JournalTitle>Eur J Pharm Biopharm.</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>19</FirstPage>
                  <LastPage>23</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXlvVKqtrg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Pedersen M. Isolation and antimycotic effect of a genuine miconazole β-cyclodextrin complex.<Emphasis Type="Italic">Eur J Pharm Biopharm.</Emphasis> 1994;40:19–23.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Piel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Evrard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Fillet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Llabres</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Delattre</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins</ArticleTitle>
                  <JournalTitle>Int J Pharm.</JournalTitle>
                  <VolumeID>169</VolumeID>
                  <FirstPage>15</FirstPage>
                  <LastPage>22</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0378-5173(98)00103-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXksF2ls7c%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Piel G, Evrard B, Fillet M, Llabres G, Delattre L. Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 1998;169:15–22.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Rajewski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VJ</Initials>
                    <FamilyName>Stella</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery</ArticleTitle>
                  <JournalTitle>J Pharm Sci.</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>1142</FirstPage>
                  <LastPage>1165</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8923319</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/js960075u</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XmtFKgu70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 1996;85:1142–1165.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Tenjarla</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Puranajoti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Kasina</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Mandal</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery</ArticleTitle>
                  <JournalTitle>J Pharm Sci.</JournalTitle>
                  <VolumeID>87</VolumeID>
                  <FirstPage>425</FirstPage>
                  <LastPage>429</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9548893</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/js970361l</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXhs1Chs70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tenjarla S, Puranajoti P, Kasina R, Mandal T. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 1998;87:425–429.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Hostetler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LH</Initials>
                    <FamilyName>Hanson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Stevens</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Effect of cyclodextrin on the pharmacology of antifungal oral azoles</ArticleTitle>
                  <JournalTitle>Antimicrob Agents Chem.</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>477</FirstPage>
                  <LastPage>480</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38XhtFent7s%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1128/AAC.36.2.477</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles.<Emphasis Type="Italic">Antimicrob Agents Chem.</Emphasis> 1992;36:477–480.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Hees</FamilyName>
                    <Particle>Van</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Piel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Evrard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Otte</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Thunus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Delattre</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Application of supercritical fluid carbon dioxide for the preparation of a piroxicam-β-cyclodextrin inclusion compound</ArticleTitle>
                  <JournalTitle>Pharm Res.</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>1864</FirstPage>
                  <LastPage>1870</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10644075</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1018955410414</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Van Hees T, Piel G, Evrard B, Otte X, Thunus L, Delattre L. Application of supercritical fluid carbon dioxide for the preparation of a piroxicam-β-cyclodextrin inclusion compound.<Emphasis Type="Italic">Pharm Res.</Emphasis> 1999;16:1864–1870.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Charoenchaitrakool</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Dehghani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NR</Initials>
                    <FamilyName>Foster</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrin</ArticleTitle>
                  <JournalTitle>Int J Pharm.</JournalTitle>
                  <VolumeID>239</VolumeID>
                  <FirstPage>103</FirstPage>
                  <LastPage>112</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12052695</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0378-5173(02)00078-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XktFektro%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Charoenchaitrakool M, Dehghani F, Foster NR. Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrin.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 2002;239:103–112.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Lai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Locci</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Piras</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Porcedda</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Lai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Marongiu</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Imazalil-cyclomaltoheptaose (β-cyclodextrin) inclusion complex: preparation by supercritical carbon dioxide and<Superscript>13</Superscript>C CPMAS and<Superscript>1</Superscript>H NMR characterization</ArticleTitle>
                  <JournalTitle>Carbohydr Res.</JournalTitle>
                  <VolumeID>338</VolumeID>
                  <FirstPage>2227</FirstPage>
                  <LastPage>2232</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14553984</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0008-6215(03)00358-6</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXnvFGit70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lai S, Locci E, Piras A, Porcedda S, Lai A, Marongiu B. Imazalil-cyclomaltoheptaose (β-cyclodextrin) inclusion complex: preparation by supercritical carbon dioxide and<Superscript>13</Superscript>C CPMAS and<Superscript>1</Superscript>H NMR characterization.<Emphasis Type="Italic">Carbohydr Res.</Emphasis> 2003;338:2227–2232.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Barillaro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Bertholet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Henry de Hassonville</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide</ArticleTitle>
                  <JournalTitle>J Pharm Pharm Sci.</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>378</FirstPage>
                  <LastPage>388</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15576020</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXivVChu7Y%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Barillaro V, Bertholet P, Henry de Hassonville S, et al. Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide.<Emphasis Type="Italic">J Pharm Pharm Sci.</Emphasis> 2004;7:378–388.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TT</Initials>
                    <FamilyName>Kararli</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Comparison of the gatrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals</ArticleTitle>
                  <JournalTitle>Biopharm Drug Dispos.</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>351</FirstPage>
                  <LastPage>380</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8527686</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/bdd.2510160502</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXmvFOls70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kararli TT. Comparison of the gatrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals.<Emphasis Type="Italic">Biopharm Drug Dispos.</Emphasis> 1995;16:351–380.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Davis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Illum</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Hinchcliffe</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Gastrointestinal transit of dosage forms in the pig</ArticleTitle>
                  <JournalTitle>J Pharm Pharmacol.</JournalTitle>
                  <VolumeID>53</VolumeID>
                  <FirstPage>33</FirstPage>
                  <LastPage>39</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11206190</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1211/0022357011775163</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXht1Shsr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Davis SS, Illum L, Hinchcliffe M. Gastrointestinal transit of dosage forms in the pig.<Emphasis Type="Italic">J Pharm Pharmacol.</Emphasis> 2001;53:33–39.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Larsen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BH</Initials>
                    <FamilyName>Jensen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HP</Initials>
                    <FamilyName>Olesen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Larsen</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution</ArticleTitle>
                  <JournalTitle>Pharm Res.</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>915</FirstPage>
                  <LastPage>919</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1279651</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1015805000595</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38XlvFygsbg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Larsen F, Jensen BH, Olesen HP, Larsen P. Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution.<Emphasis Type="Italic">Pharm Res.</Emphasis> 1992;9:915–919.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Hildebrand</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FM</Initials>
                    <FamilyName>McDonald</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Windt-Hanke</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Characterization of oral sustained release preparations of iloprost in the pig model by plasma level monitoring</ArticleTitle>
                  <JournalTitle>Prostaglandins.</JournalTitle>
                  <VolumeID>41</VolumeID>
                  <FirstPage>473</FirstPage>
                  <LastPage>486</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1713701</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0090-6980(91)90053-I</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXkslyksLc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hildebrand H, McDonald FM, Windt-Hanke E. Characterization of oral sustained release preparations of iloprost in the pig model by plasma level monitoring.<Emphasis Type="Italic">Prostaglandins.</Emphasis> 1991;41:473–486.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Piel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Evrard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Hees</FamilyName>
                    <Particle>Van</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Delattre</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution</ArticleTitle>
                  <JournalTitle>Int J Pharm.</JournalTitle>
                  <VolumeID>180</VolumeID>
                  <FirstPage>41</FirstPage>
                  <LastPage>45</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10089290</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0378-5173(98)00403-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXhvFCru7Y%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Piel G, Evrard B, Van Hees T, Delattre L. Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 1999;180:41–45.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>US Food and Drug Administration Center for Drug Evaluation and Research</InstitutionalAuthorName>
                  <Year>2001</Year>
                  <BookTitle>Bioanalytical Method Validation</BookTitle>
                  <PublisherName>FDA Office of Training and Communication, Division of Communication Management, Drug Information Branch</PublisherName>
                  <PublisherLocation>Rockville, Maryland</PublisherLocation>
                </BibBook>
                <BibUnstructured>US Food and Drug Administration Center for Drug Evaluation and Research.<Emphasis Type="Italic">Bioanalytical Method Validation</Emphasis>. Rockville, Maryland: FDA Office of Training and Communication, Division of Communication Management, Drug Information Branch, 2001.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Hees</FamilyName>
                    <Particle>Van</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Piel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Henry de Hassonville</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Evrard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Delattre</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectroscopy and differential scanning calorimetry</ArticleTitle>
                  <JournalTitle>Eur J Pharm Sci.</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>347</FirstPage>
                  <LastPage>353</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11988396</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0928-0987(02)00018-0</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Van Hees T, Piel G, Henry de Hassonville S, Evrard B, Delattre L. Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectroscopy and differential scanning calorimetry.<Emphasis Type="Italic">Eur J Pharm Sci.</Emphasis> 2002;15:347–353.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>VJ</Initials>
                    <FamilyName>Stella</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VM</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EA</Initials>
                    <FamilyName>Zannou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Zia</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Mechanisms of drug release from cyclodextrin complexes</ArticleTitle>
                  <JournalTitle>Adv Drug Deliv Rev.</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>3</FirstPage>
                  <LastPage>16</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10837705</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0169-409X(98)00052-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXksFegtg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes.<Emphasis Type="Italic">Adv Drug Deliv Rev.</Emphasis> 1999;36:3–16.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Uekama</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Hirayama</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Irie</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Cyclodextrin drug carrier systems</ArticleTitle>
                  <JournalTitle>Chem Rev.</JournalTitle>
                  <VolumeID>98</VolumeID>
                  <FirstPage>2045</FirstPage>
                  <LastPage>2076</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11848959</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/cr970025p</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXksV2itr0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems.<Emphasis Type="Italic">Chem Rev.</Emphasis> 1998;98:2045–2076.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Savolainen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Jarvinen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Matilainen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Jarvinen</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Improved dissolution and bioavailability of phenytoin by sulfobutylether-β-cyclodextrin ((SBE) 7m-β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) complexation</ArticleTitle>
                  <JournalTitle>Int J Pharm.</JournalTitle>
                  <VolumeID>165</VolumeID>
                  <FirstPage>69</FirstPage>
                  <LastPage>78</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0378-5173(98)00004-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXis1Wqsr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Savolainen J, Jarvinen K, Matilainen L, Jarvinen T. Improved dissolution and bioavailability of phenytoin by sulfobutylether-β-cyclodextrin ((SBE) 7m-β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) complexation.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 1998;165:69–78.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LS</Initials>
                    <FamilyName>Koester</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JB</Initials>
                    <FamilyName>Bertuol</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KR</Initials>
                    <FamilyName>Groch</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Bioavailability of carbamazepine: β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets</ArticleTitle>
                  <JournalTitle>Eur J Pharm Sci.</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>201</FirstPage>
                  <LastPage>207</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15158905</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ejps.2004.03.010</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXkt1Slur0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Koester LS, Bertuol JB, Groch KR, et al. Bioavailability of carbamazepine: β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets.<Emphasis Type="Italic">Eur J Pharm Sci.</Emphasis> 2004;22:201–207.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
